BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17786712)

  • 1. T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature.
    El Weshi A; Akhtar S; Mourad WA; Ajarim D; Abdelsalm M; Khafaga Y; Bazarbashi S; Maghfoor I
    Leuk Lymphoma; 2007 Sep; 48(9):1764-73. PubMed ID: 17786712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center.
    Prakash G; Sharma A; Raina V; Kumar L; Sharma MC; Mohanti BK
    Ann Hematol; 2012 Oct; 91(10):1603-11. PubMed ID: 22584851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature.
    Zheng SM; Zhou DJ; Chen YH; Jiang R; Wang YX; Zhang Y; Xue HL; Wang HQ; Mou D; Zeng WZ
    World J Gastroenterol; 2017 Jun; 23(24):4467-4472. PubMed ID: 28706431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
    Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
    Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis.
    Bouabdallah R; Mounier N; Guettier C; Molina T; Ribrag V; Thieblemont C; Sonet A; Delmer A; Belhadj K; Gaulard P; Gisselbrecht C; Xerri L
    J Clin Oncol; 2003 Apr; 21(7):1271-7. PubMed ID: 12663714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
    Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP.
    Kim YS; Ji JH; Ko YH; Kim SJ; Kim WS
    Acta Haematol; 2014; 131(3):156-61. PubMed ID: 24192382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma.
    Møller MB; Pedersen NT; Christensen BE
    Am J Hematol; 2003 Oct; 74(2):94-8. PubMed ID: 14508794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group.
    Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO;
    Leuk Lymphoma; 2003 Nov; 44(11):1903-10. PubMed ID: 14738141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
    Tsirigotis P; Economopoulos T; Rontogianni D; Dervenoulas J; Papageorgiou E; Bollas G; Mantzios G; Kalantzis D; Koumarianou A; Raptis S
    Oncology; 2001; 61(4):257-64. PubMed ID: 11721171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of localized diffuse large B-cell lymphoma in younger patients.
    Møller MB; Christensen BE; Pedersen NT
    Cancer; 2003 Aug; 98(3):516-21. PubMed ID: 12879468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis and treatment of primary colorectal non-Hodgkin's lymphoma: analysis of 52 cases].
    Huang S; Zheng ZX; Xu Q; Yuan XH
    Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):305-8. PubMed ID: 23985262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.